Abstract Number: 886 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries, including…Abstract Number: 2523 • 2018 ACR/ARHP Annual Meeting
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate…Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…Abstract Number: 409 • 2017 ACR/ARHP Annual Meeting
An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) tend to have higher absolute neutrophil count (ANC) values compared to healthy individuals.1 Baricitinib (BARI), an oral, selective Janus…Abstract Number: 415 • 2017 ACR/ARHP Annual Meeting
Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1/JAK2.1 In the European Union, bari is approved for the treatment of moderate…Abstract Number: 418 • 2017 ACR/ARHP Annual Meeting
Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline
Background/Purpose: Baricitinib (BARI), an oral inhibitor of Janus kinase (JAK)1 and JAK2, is being developed for the treatment of RA. RA-BEGIN (NCT01711359) was a phase…Abstract Number: 502 • 2017 ACR/ARHP Annual Meeting
Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo
Background/Purpose: Baricitinib (BARI), is an oral Janus kinase (JAK)1/JAK2 selective inhibitor for treatment of patients with moderately to severely active RA. RA-BEAM was a phase…Abstract Number: 505 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy
Background/Purpose: Upadacitinib, a selective JAK1 inhibitor, demonstrated favorable efficacy in two Phase 2 studies in subjects with moderate to severe rheumatoid arthritis (RA) who had…Abstract Number: 512 • 2017 ACR/ARHP Annual Meeting
Efficacy Response to Baricitinib Based on Baseline Characteristics in Patients Who Are Inadequate Responders to Conventional DMARD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease and some patients (pts) have an inadequate response (IR) to conventional DMARDs (csDMARDs). Baricitinib is an oral,…Abstract Number: 513 • 2017 ACR/ARHP Annual Meeting
Time to Achieve Moderate/Low Disease Activity and Remission in RA Patients on Baricitinib Compared to Adalimumab, Methotrexate, and Placebo
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1/2 inhibitor1, has shown efficacy in DMARD naïve RA patients (pts)2 and in pts with inadequate response…Abstract Number: 530 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Background/Purpose: Janus kinases (JAKs) play an important role in intracellular signaling for multiple cytokines in the pathogenesis of RA. Baricitinib is an oral, selective JAK…Abstract Number: 537 • 2017 ACR/ARHP Annual Meeting
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…Abstract Number: 1821 • 2017 ACR/ARHP Annual Meeting
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Background/Purpose: In patients (pts) with active RA and inadequate response (IR) to DMARDs, phase 3 studies demonstrated efficacy of baricitinib (2-mg and 4-mg). Larger, more…Abstract Number: 2352 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Safety during Treatment with Baricitinib in Rheumatoid Arthritis
Background/Purpose: Baricitinib (BARI) is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 approved in the EU for the treatment of active RA. Patients…Abstract Number: 1644 • 2016 ACR/ARHP Annual Meeting
Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor showing good efficacy and safety in Phase 2B studies in rheumatoid arthritis (RA) patients. The…
ACR Meeting Abstracts